Novo Nordisk A/S vs Eli Lilly and: Fair Value & Quality
Both stocks run through our valuation models. Here is how Novo Nordisk A/S (NOVO-B) and Eli Lilly and (LLY) compare, as of Aug 30, 2026.
As of Aug 30, 2026, Fair Value Calculator sees Novo Nordisk A/S as the more attractively valued of the two: Novo Nordisk A/S trades at DKK 296 versus a fair value of DKK 409 (+39%), while Eli Lilly and trades at $1,175 versus $389 (-67%).
Novo Nordisk A/S
NOVO-B.CO · DKK · Health Care
+39%
upside to fair value
undervalued
PriceDKK 296
Fair ValueDKK 409
Quality59/100
Eli Lilly and
LLY · USD · Health Care
-67%
upside to fair value
overvalued
Price$1,175
Fair Value$389
Quality69/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Novo Nordisk A/SEli Lilly and
Valuation
12.3×P/E (TTM)42.2×
4.45×P/S (TTM)14.67×
7.52×P/B39.94×
8.9×EV/EBITDA30.2×
3.77×PEG1.54×
4.0%Dividend yield0.5%
DKK 11.70Dividend per share$6.23
Profitability
37%Net margin35%
62%Operating margin49%
71%Return on equity107%
19%Return on assets21%
Growth
24%Revenue growth (YoY)56%
20.4%Avg. growth/yr (3Y)31.7%
19.5%Avg. growth/yr (5Y)21.6%
Balance & size
0.58×Debt / equity1.54×
$226BMarket cap$1.1T
expensiveGrowth qualitymixed
Novo Nordisk A/S leads: 8 to 6 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Novo Nordisk A/Sof which business quality 57 · market factors 47Eli Lilly andof which business quality 65 · market factors 78
ProfitabilityMargins and returns on capital today
84
85
Quality GrowthAre margins and returns improving?
31
86
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
0
15
Low VolatilityCalm price path (market factor)
63
77
MomentumPrice trend over the last 3–12 months (market factor)
50
70
52W MomentumDistance to the 52-week high (market factor)
25
94
Net IssuanceBuybacks instead of dilution
87
93
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Novo Nordisk A/S
DCF ModelsDKK 292
Earnings-BasedDKK 249
Dividend DiscountDKK 222
MultiplesDKK 348
Asset-BasedDKK 29.23
Growth DCFDKK 171
Economic ProfitDKK 281
Growth EarningsDKK 426
16 of 26 models see the stock below the current price.
Eli Lilly and
DCF Models$334
Earnings-Based$239
Dividend Discount$115
Multiples$358
Asset-Based$19.94
Growth DCF$187
Economic Profit$347
Growth Earnings$375
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Novo Nordisk A/S
Bear DKK 206Fair Value DKK 409Bull DKK 565
DKK 296 = current price (white tick)
Eli Lilly and
Bear $216Fair Value $389Bull $582
$1,175 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Novo Nordisk A/S · Health Care
Quality score59 · above median
Fair value upside+39% · Top 25%
Eli Lilly and · Health Care
Quality score69 · Top 25%
Fair value upside-67% · bottom 25%
Bottom line
As of Aug 30, 2026, Fair Value Calculator sees Novo Nordisk A/S as the more attractively valued of the two: Novo Nordisk A/S trades at DKK 296 versus a fair value of DKK 409 (+39%), while Eli Lilly and trades at $1,175 versus $389 (-67%).
Eli Lilly and has the higher quality score (69/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.
